Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Jashodeep Datta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2869-1571; OpenAlex author ID A5001060160; NIH RePORTER profile ID 16173868. Sources: OpenAlex.

Their work

Papers
30 (first author 0, last author 11)
Trials
0
Grants
1
Labs led
1
Collaborators
109
Papers, trials and grants by year

2021: 3 papers · 2022: 6 papers · 2023: 7 papers · 2024: 2 papers · 2025: 4 papers · 2026: 8 papers, 1 grant

Papers 30

  1. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Co-author DOI 10.1016/j.devcel.2026.04.001↗
  2. Immune-driven stromal inflammation in pancreatic cancer within a microfluidic platform. Co-author DOI 10.1088/1758-5090/ae7b09↗
  3. IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer. Last author DOI 10.1172/jci.insight.202487↗
  4. Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18664-0↗
  5. ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18846-w↗
  6. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  7. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  8. Leveraging the perioperative window in pancreatic cancer: lessons from the PROSPER trial. Last author DOI 10.21037/gs-2026-0166↗
  9. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  10. SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer : A Multic… Co-author DOI 10.1097/sla.0000000000006966↗
  11. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  12. Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. Last author DOI 10.1245/s10434-025-17024-2↗
  13. Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer. Last author DOI 10.1080/2162402x.2024.2326694↗
  14. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1200↗
  15. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. Co-author DOI 10.1002/jso.27287↗
  16. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-22-1046↗
  17. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-22-0329↗
  18. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Last author DOI 10.1200/po.23.00152↗
  19. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Last author DOI 10.1245/s10434-022-12741-4↗
  20. ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture? Last author DOI 10.1245/s10434-022-12843-z↗
  21. Texture Analysis Identifies Distinct Radiomic Signals Associated with Survival in Hispanic Patients with Pancreatic Cancer. Last author DOI 10.1245/s10434-022-13013-x↗
  22. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  23. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
  24. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Co-author DOI 10.1053/j.gastro.2022.07.076↗
  25. Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. Co-author DOI 10.1080/19490976.2022.2096328↗
  26. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Last author DOI 10.1245/s10434-022-11804-w↗
  27. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy resp… Last author DOI 10.7554/elife.78921↗
  28. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Co-author DOI 10.1001/jamasurg.2020.5676↗
  29. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Co-author DOI 10.1097/sla.0000000000004471↗
  30. Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last? Co-author DOI 10.1245/s10434-020-09400-x↗

Grants 1

  1. Disrupting MDSC-fibroblast interactions to overcome chemoimmunotherapy resistance in pancreatic cancer R37CA292843↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nipun B. Merchant · 22 shared papers, 2021–2026 · strength 4.06
  2. Peter J. Hosein · 10 shared papers, 2022–2026 · strength 2.23
  3. Anna Bianchi · 6 shared papers, 2023–2026 · strength 1.31
  4. Haleh Amirian · 6 shared papers, 2023–2026 · strength 1.30
  5. Caitlin A. Hester · 5 shared papers, 2023–2026 · strength 1.27
  6. Erin M. Dickey · 5 shared papers, 2024–2026 · strength 1.25
  7. Shishir Kumar Maithel · 7 shared papers, 2021–2025 · strength 1.19
  8. Iago De Castro Silva · 7 shared papers, 2022–2024 · strength 0.99
  9. Siddharth Mehra · 6 shared papers, 2022–2024 · strength 0.85
  10. Mary P Martos · 3 shared papers, 2025–2026 · strength 0.81
  11. David A. Kooby · 5 shared papers, 2021–2023 · strength 0.74
  12. Austin R. Dosch · 5 shared papers, 2022–2024 · strength 0.71
  13. Samara P. Singh · 5 shared papers, 2022–2024 · strength 0.71
  14. Nagaraj S. Nagathihalli · 5 shared papers, 2022–2024 · strength 0.71
  15. Ifeanyichukwu Chinedu Ogobuiro · 4 shared papers, 2023 · strength 0.68
  16. Syed Ameen Ahmad · 4 shared papers, 2021–2025 · strength 0.62
  17. Daniel Erik Abbott · 4 shared papers, 2022–2025 · strength 0.62
  18. Gregory C. Wilson · 4 shared papers, 2021–2023 · strength 0.57
  19. Gretel Terrero · 2 shared papers, 2026 · strength 0.56
  20. Alexander A. Parikh · 3 shared papers, 2023–2025 · strength 0.51
  21. Bradley Norman Reames · 2 shared papers, 2026 · strength 0.50
  22. José Oberholzer · 2 shared papers, 2026 · strength 0.50
  23. Ning Pu · 2 shared papers, 2026 · strength 0.50
  24. Chunmeng Zhang · 2 shared papers, 2026 · strength 0.50
  25. Dilmurodjon Eshmuminov · 2 shared papers, 2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.